Moxonidine is a selective agonist at the imidazoline receptor subtype 1 with very weak binding affinity for α2-adrenoceptors, used as antihypertensive agent[3]. Hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM(rostral ventrolateral medulla)[4]. Moxonidine binds with an affinity for the imidazoline I1 receptor that is 33 times more effective than is alpha2-receptor binding. There is a regression of left-ventricular hypertrophy after moxonidine was given for 6 months. Following oral administration the half-life (Tmax) is about 1 h. Moxonidine is highly bioavailable, approaching 90%[5]. Moreover, moxonidine (10 μmol·L-1) significantly inhibited the frequency of spontaneous EPSCs in both inspiratory-activated and inspiratory-inhibited AVPNs (airway vagal preganglionic neurons). Thus moxonidine inhibits the excitatory inputs to AVPNs via activation of both α2-adrenoceptors and imidazoline I1 receptors, and suggest that physiologically both of these two types of receptors are involved in the central regulation of airway vagal activity at preganglionic level[6].
Australia, Victoria
... 展开 >>
Ballarat Health Service Psychiatric Services
Recruiting
Ballarat, Victoria, Australia
Principal Investigator: Abdul Khalid
Sub-Investigator: Rajul Tandon
Sub-Investigator: Sonia Ghai
Sub-Investigator: Arup Dhar
Sub-Investigator: Sarah Tremethick
Sub-Investigator: Jennifer Grigo
Sub-Investigator: Pella Karalis
Monash Medical Centre - Monash Health
Recruiting
Clayton, Victoria, Australia
Principal Investigator: David Barton
Sub-Investigator: Arup Dhar
Sub-Investigator: Sarah Tremethick
Sub-Investigator: Jennifer Grigo
Sub-Investigator: Krishna Vaddadi
Alfred and Baker Medical Unit - Alfred Hospital
Recruiting
Melbourne, Victoria, Australia
Principal Investigator: Gavin Lambert
Sub-Investigator: Markus Schlaich
Sub-Investigator: Elisabeth Lambert
Sub-Investigator: Murray Esler
Sub-Investigator: Geoff Head
Sub-Investigator: Dagmara Hering
Sub-Investigator: Nina Eikelis
Sub-Investigator: Carolina Ika Sari
Sub-Investigator: Petra Marusic
Sub-Investigator: Toni Rice
Sub-Investigator: Mariee Grima
Sub-Investigator: David Barton
Sub-Investigator: Arup Dhar
Sub-Investigator: Sarah Tremethick
Sub-Investigator: Nora Straznicky
Sub-Investigator: John Dixon
Sub-Investigator: Jennifer Grigo
Sub-Investigator: Donna Vizi
Sub-Investigator: Louise Hammond
Baker IDI Heart & Diabetes Institute
Recruiting
Melbourne, Victoria, Australia
Principal Investigator: Gavin Lambert
Sub-Investigator: Markus Schlaich
Sub-Investigator: Elisabeth Lambert
Sub-Investigator: Murray Esler
Sub-Investigator: Geoff Head
Sub-Investigator: Dagmara Hering
Sub-Investigator: Nina Eikelis
Sub-Investigator: Carolina Ika Sari
Sub-Investigator: Petra Marusic
Sub-Investigator: Toni Rice
Sub-Investigator: Mariee Grima
Sub-Investigator: David Barton
Sub-Investigator: Arup Dhar
Sub-Investigator: Sarah Tremethick
Sub-Investigator: Nora Straznicky
Sub-Investigator: John Dixon
Sub-Investigator: Jennifer Grigo
Sub-Investigator: Donna Vizi
Sub-Investigator: Louise Hammond 收起 <<
Australia, Victoria
... 展开 >>
Alfred & Baker Medical Unit
Recruiting
Melbourne, Victoria, Australia
Principal Investigator: Markus P Schlaich, MD
Principal Investigator: Gavin W Lambert, BSc PhD 收起 <<
搜索
